Introduction
Echinococcus multilocularis is one of four species of hydatid cyst-forming tapeworms (genus: Echinococcus) that occur as adults in the small intestine of carnivores (principally canids). The larval stages (hydatids) of Echinococcus spp. grow in the organs or tissues of a wide range of mammalian intermediate hosts (principally rodents and ungulates) including humans. All four species of Echinococcus are potentially zoonotic, but E. multilocularis is the most pathogenic, while E. granulosus is the most common cause of human hydatid disease, also termed cystic echinococcosis or cystic hydatidosis. Accidental ingestion of the microscopic egg stage of E. multilocularis may eventually result in the disease termed human alveolar echinococcosis. Human alveolar echinococcosis is a potentially fatal, chronically progressive hepatic infestation, that is characterized by a long asymptomatic period in which development of an invasive tumour-like multi-vesiculated and exogenously budding lesion occurs. The parasitic lesion exhibits dense granulomatous infiltration and microcalcifications, and eventually necrotic cavitation may occur. There is, in addition, a risk of metastases in advanced alveolar echinococcosis, usually resulting in secondary lesions in the lungs and/or brain. A fatal outcome may occur in 495% of untreated patients within a 10-year period following diagnosis. Radical liver resection is the only curative measure for a subset of alveolar echinococcosis patients with localized liver lesion(s). Liver transplantation in alveolar echinococcosis patients with liver failure has also been undertaken. Benzimidazole drug therapy, at high daily doses, (410 mg/kg/day), over the patient's lifetime can significantly extend survival times, but current therapy is normally parasitostatic rather than parasitocidal.
E. multilocularis occurs across the northern hemisphere mainly in upland ecosystems or in the holarctic zone. Transmission occurs between foxes and sylvatic rodent or other small mammal species and may be relatively common in wild canid hosts such as the red fox. Although human alveolar echinococcosis is a rare helminthic zoonosis, due to its serious pathology, incidence rates 40.1 per 100 000 may be considered of public health significance. New cases occur annually in western and central Europe, the Near East (Turkey, Iran), eastern Russia, northwest China and northern Japan. The disease was formerly common in western Alaska amongst some Inuit populations, and the parasite still occurs in wildlife in Alaska, and active transmission is maintained in the red fox and coyote in north central USA. Concern is currently growing in parts of Europe and Japan about the potential spread of the parasite and potential risks for increased incidence of human alveolar echinococcosis. This review highlights some recent studies and reports, that contribute to development of knowledge and progress in aspects of the pathogenesis, diagnosis, and treatment of human alveolar echinococcosis and an increase in our understanding of the epidemiology and transmission ecology of the causative organism.
Parasite biology and pathogenesis
Humans are an aberrant host for the metacestode (larval stage) of E. multilocularis. This fact is reflected in the much slower growth rate (years) and frequent lack of asexual protoscolex production in the metacestode, compared to natural or experimental rodent infections in which the metacestode tissues grow rapidly and usually become highly fertile (produce protoscoleces) within 2-4 months. The larval parasite may eventually kill its natural host, but due to the short lifespan of most rodents and small mammals, predation by foxes is likely to occur before parasite induced mortality. Transmission to the fox definitive host occurs as a result of the normal predator-prey feeding behaviour of the canid host. After ingestion of an infected rodent the newly evaginated protoscoleces transform and develop into the small adult tapeworms (1.2-4.5 mm when mature) over 28-35 days post-infection in the small intestine of the fox. Adult tapeworms probably live for 6-12 months in the fox intestine. Eggs in the terminal segment (gravid proglottis) are released with fox faeces to contaminate the environment, where they may remain viable for months, even under freezing conditions (to -508C). Once ingested eggs hatch to release an active six-hooked embryo, or oncosphere, which penetrates the mucosa of the small intestine and passes (via the hepatic portal vein) to the liver where it rapidly vesiculates. Experimental studies on E. multilocularis are usually limited to 'artificial' infection of laboratory rodents with metacestode tissues injected intraperitoneally, intrahepatically or intravenously. Manipulations with the infective egg stage, however, are difficult and biohazardous, requiring pathogen level P3 containment, and possibly also maintenance of experimental canids (dogs, foxes).
Experimental infection and growth of adult E. multilocularis tapeworms in the intestines of immunosuppressed hamsters and gerbils (rather than in canids) has recently been re-reported [1] but numbers of adults recovered is small, and egg production very variable. The adult stage can also be cultured in vitro from protoscoleces but development is truncated. More promising research by Swiss workers using an in-vitro cell-free culture system for the larval stage, has been published, in which metacestode tissue blocks were cultured and parasite microvesicles budded off after 1-2 weeks and eventually also to produce protoscoleces [2 . ]. Development of an acellular, glycan-rich, laminated layer is a characteristic feature of the genus Echinococcus (its presence is also useful for histopathological confirmation), and this layer also develops in vitro in microvesicles of E. multilocularis. Presence of a physically intact laminated layer was recently shown to be a prerequisite for successful in-vivo establishment of culture derived vesicles of E. multilocularis [3 . . ]. The laminated layer of the metacestode of E. multilocularis may also act indirectly to modulate host immune responses through carbohydrate antigen (Em2) expression in a T-cellindependent manner [4 . ]. Purification of the Em2 antigen by size exclusion chromatography followed by mass spectrometry analysis, indicated that this laminated layer derived molecule is a novel mucin-type glycosylated protein with structural properties, and was composed of an O-glycan core and branched saccharides attached to serine and threonine residues [5 . . ].
The glycan rich laminated layer is secreted in vivo, by the cellular germinal layer of the parasite within 7-14 days after post-oncosphere establishment. Cells from the more delicate germinal layer are thought to be responsible for metastatic spread of the lesions. About 98% of primary lesions occur in the liver. Unlike cystic echinococcosis due to E. granulosus, experimental invivo studies indicate that protoscoleces produced by the metacestode of E. multilocularis are not responsible for secondary echinococcosis, rather it is due to germinal cells, or growth of preformed microvesicles produced from the larval tissues.
Primary hepatic development of alveolar echinococcosis in humans results from establishment of an oncosphere that hatches in the small intestine after egg ingestion, which then enters the blood stream. The multicellular oncosphere (25-30 mm) is susceptible to antibody dependent complement mediated damage as are postoncosphere stages up to around 10-14 days postinfection. After this period vesicular development and growth of the laminated layer helps to protect the early metacestode against antibody and cell-mediated host immune responses. Vaccination of susceptible mice using an E. multilocularis recombinant oncosphere antigen called EM95 (a homologue of EG95, a highly protective antigen previously identified from E. granulosus oncospheres) resulted in up to 83% protection against oncosphere establishment [6 . ]. Other studies have shown that over-expression of a metacestode protein, designated 14-3-3, appeared to be associated with proliferation of the germinal layer of the E. multilocularis metacestode following post-oncosphere development, and remarkably a recominant form of this protein (E14t) provided an impressive 97% protection in mice against egg challenge, though not as expected against the developing or already established metacestodes [7 . . ]. The 14-3-3 metacestode derived protein must therefore also be expressed in the oncosphere stage, and it is likely to be an important molecule in post-oncosphere establishment. After metacestode establishment, however, cellular immunity in humans restricts expansion of the liver lesion(s) resulting in the chronic course typical in human alveolar echinococcosis patients. High counts of CD4 + T cells in hepatic granuloma was correlated in patients with abortive alveolar echinococcosis lesions or slower disease progression, while CD8 + T cells were invariably present in chronic active alveolar echinococcosis lesions [8] . The latter CD8 + T-cell population, in contrast to CD4 + T cells, was also elevated in the peripheral blood of patients with chronic alveolar echinococcosis and exhibited oligoclonality with putative hyporesponsiveness [9 . ]. Parasite induced immune evasion mechanisms may also include over-production of the anti-inflammatory cytokine interleukin-10 (IL-10). IL-10 has been shown to be produced by CD8 + T cells and by mononuclear cells within the parasitic alveolar echinococcosis lesion itself, and it may act by inhibition of interferon-g production by granuloma cells [10 . ]. Genetic correlates of resistance or susceptibility to human alveolar echinococcosis disease have been indicated by analysis of human leucocyte antigen markers in large groups of European and Chinese alveolar echinococcosis patients. The human leucocyte antigen DR11 allele was associated with protection, and human leucocyte antigen DR3/4 with severe alveolar echinococcosis disease manifestations. A phenotypic outcome of the latter trait may be increased recruitment of CD8 + T cells with associated IL-10 secretion [11,12 . ].
Diagnosis and detection
As a space occupying lesion, diagnosis of human hepatic alveolar echinococcosis should be achieved first and foremost using imaging techniques, especially ultrasound, computerized tomography and/or magnetic resonance imaging (MRI). Laboratory diagnosis, primarily serology for specific antibody detection, is important for confirmation of alveolar echinococcosis, and serological testing may also be useful for primary screening and in epidemiological studies in endemic communities. In a German study of 30 alveolar echinococcosis patients most hepatic lesions were detected by CT, followed by MRI (95%) and ultrasound (56%). Differences in image resolution were reflected in detection of small lesions 55 mm by computerized tomography/MRI, and lesions 57 mm by ultrasound. MRI was less effective for (Table 1) is a useful development and should be applied in clinical and communitybased screening programmes.
Immunodiagnosis of human alveolar echinococcosis is useful, effective and generally highly sensitive and Table 1 . Hepatic localization in the PNM system for classification of human alveolar echinococcosis PX Primary lesion cannot be assessed PO No detectable lesion in the liver P1 Peripheral lesions without proximal vascular and/or biliary involvement P2 Central lesions with proximal vascular and/or biliary involvement of one lobe P3 Central lesions with biliary vascular and biliary involvement of both lobes and/or with involvement of two hepatic veins P4 Any liver lesion with extension along the vessels and the biliary tree
specific, especially if more than one test is used. Seroconversion is invariably high (490%) in human alveolar echinococcosis, in contrast to human cystic echinococcosis (*70% of cases are seropositive), so sensitivity may be expected to be 90% or more in advanced alveolar echinococcosis patients using native or recombinant antigens for antibody detection. Native Em2 antigen, an immunodominant laminated layerassociated carbohydrate antigen, alone or mixed (Em 2 Plus) with recombinant Em 10 (a cytovillin-like molecule -also called 11/3-10), is highly specific (494%) for human alveolar echinococcosis using enzyme-linked immunosorbent assay (ELISA), and only a very small proportion of cystic echinococcosis cases were crossreactive [16 . ]. An immunoblot detectable antigen called Em18, which is actually a small degradation product of EM10, has now been cloned and a recombinant Em18-ELISA developed. The reported sensitivity of the recombinant Em18-ELISA was 87% with 97% specificity versus cystic echinococcosis disease, and the test gave good concordance with Em18 immunoblot results [17 . . ,18]. Antibody levels against Em18 antigen may also aid in long-term post treatment surveillance of alveolar echinococcosis patients after combined resection and albendazole therapy [19] . Direct detection or amplification of E. multilocularis DNA in parasite samples or biopsied material from patients is also considered potentially useful for confirmation of alveolar echinococcosis, and may aid in assessment of anti-parasite therapy [16 . ].
In endemic communities in Europe, China and Japan, active mass screening programmes using ultrasound or serology as the primary screening tool, have helped to detect asymptomatic or undiagnosed alveolar echinococcosis cases, that have benefited from early and possibly curative liver resection of isolated lesion(s). In the south Gansu alveolar echinococcosis focus in northwest China [20 . . ], at least one abnormal ultrasound image was detected in 630 out of 2482 volunteers, and typical alveolar echinococcosis lesions were identified in 84 subjects (3.4%), of which 96% were seropositive in one or more tests using Em2 antigen, Em18 antigen or crude Echinococcus extracts (EgCF, EmC). In 46 cases of alveolar echinococcosis the ultrasound image was similar in appearance to a neoplastic intrahepatic mass with hyperechoic scattered calcifications and poorly defined edges; in 37 alveolar echinococcosis cases necrotic cavitation was visible on ultrasound, and in 64% of cases the lesion measured 410 cm [14 . . ]. Em2-ELISA was negative in 13 Chinese cases with typical alveolar echinococcosis lesions, while ELISA was positive in 44% of persons with calcifications 41 cm, and in 57% of persons with a nodular hyperechoic lesion in the liver [14 . . ]. These latter cases probably represent abortive and early alveolar echinococcosis lesions, respectively.
Abortive alveolar echinococcosis lesions had not been described prior to the advent and application of specific serology and the use of portable ultrasound machines in the 1980s and 1990s. Persistent seropositivity, without detectable hepatic alveolar echinococcosis lesions, could be a result of early infection, exposure and resolution, or presence of non-hepatic foci, or due to non-specific seroreactivity [21] .
Treatment
Unusually for a parasitic helminthic infection, human alveolar echinococcosis is a life-threatening disease. Once a diagnosis of alveolar echinococcosis has been made it is difficult to treat. The current treatment approach is preferably surgery, or secondarily benzimidazole chemotherapy. As stated, early detection therefore is potentially highly beneficial for a successful treatment outcome and to increase patient survival times. In untreated alveolar echinococcosis, clinical symptoms are variable and usually only follow a long asymptomatic period (5-15 years), but primarily include cholestatic jaundice (up to 45%), epigastric pain and/or dyspepsia (*35%), and in about a third of cases the disease is found incidentally during check-up for nonspecific symptoms (fatigue, weight loss, heptomegaly) [15 . . ,22 . . ]. In rural communities in under-developed regions, human alveolar echinococcosis in contrast to advanced cystic echinococcosis, may go undiagnosed and untreated and result in mortality due to unspecified 'liver disease'. Radical surgical resection of the complete alveolar echinococcosis lesion(s), especially when localized to right or left liver lobes, is the only potential curative treatment. Palliative surgery may be applied in non-resectable cases. In alveolar echinococcosis patients with chronic liver failure, transplantation has been undertaken (for at least 25 alveolar echinococcosis patients in France), however there was a high risk of alveolar echinococcosis recurrence in the donor liver, or of parasite lesion development in extrahepatic sites [15 . . ,23]. Albendazole (ABZ) at 10-15 mg/kg/day, is the drug of choice for human alveolar echinococcosis although it is primarily parasitostatic rather than curative. In a recent long-term chemotherapy study (mean 6.5 years) in Turkey in which ABZ was used to treat 23 non-resectable alveolar echinococcosis patients, a clinically beneficial outcome was observed in eight (35%) patients only, while nine cases showed progression of lesions, and none of the patients were considered cured [22 . . ] . Despite poor responses to ABZ, evidence from Swiss and Japanese patient series for non-radically operated alveolar echinococcosis cases, indicated that ABZ is a useful adjunct therapy to surgery, and that overall its use orally resulted in improved 10 year survival rates up to 80-83%, compared to 6-25% for untreated historical controls [15 . . ].
In the absence of better drugs, investigations to improve delivery and/or increase metabolism of ABZ, leading to increased serum concentrations of albendazole sulphoxide, have also been undertaken. Liposome-entrapped ABZ given orally in experimental murine secondary alveolar echinococcosis significantly reduced the parasite biomass in livers of treated animals compared to controls given free ABZ [24] . The recent development of reliable in-vitro culture systems for production of metacestode derived tissues and cells of E. multilocularis [2 . ], now provides a model system for preliminary assessment of anti-parasite activity for untested or novel compounds. Nitazoxanide (NTZ), a broad-spectrum anthelminthic also used for enteric bacteria treatment, induced high levels of alkaline phosphatase activity from E. multilocularis vesicles in culture medium and caused significant ultrastructural alterations of germinal membrane cells, and also the separation of this layer from the laminated layer. Furthermore, NTZ-treated in-vitro cultured metacestodes of E. multilocularis were nonviable when implanted into susceptible mice [25 . . ]. As NTZ is much better absorbed than ABZ following oral administration it provides an attractive potential alternative for medical treatment of human alveolar echinococcosis. Another recent study looked at the antifungal agent amphotericin B which has recognized anti-protozoan activity against Leishmania and Trypanosoma, and also appears to damage E. multilocularis metacestode vesicles over long-term in-vitro culture. However some treated cultures of E. multilocularis could still induce secondary alveolar echinococcosis in mice, and therefore amphotericin B could not be considered to be parasiticidal [26] .
Epidemiology and ecology
E. multilocularis is a natural cestode parasite of foxes and small mammals (chiefly microtine rodents) over its normal geographic range in the temperate northern hemisphere. Human alveolar echinococcosis is therefore a zoonosis that is acquired accidentally via contact with infected definitive hosts (foxes, or dogs/cats), or exposure from a contaminated environment. Risk factors for human alveolar echinococcosis in endemic regions are not well defined, but include an agricultural occupation (or activity in gardening, forestry, hunting), a history of dog/cat ownership, and residence in a rural upland landscape where 450% grassland/scrubland surrounds villages/towns [20 . . ,27] . Age and sex may also be risk factors but vary with endemic regions. In a retrospective study of 559 European alveolar echinococcosis cases diagnosed between 1982-2000 (42% diagnosed in eastern France, 23.6% in southern Germany and 21% in northeast Switzerland) 54% were female and 46% male with a medium age at diagnosis being similar at 56 years [28 . . ]. In poor agricultural communities in south Gansu (China) an active mass screening pro-gramme over 4 years identified 84 alveolar echinococcosis cases by ultrasound and serology, with a female : male ratio of 1.6 : 1, and an overall mean age of 38.7 years, but females between the ages of 30-60 years had more than twice the risk of alveolar echinococcosis compared to men [14 . . ,20 . . ]. In Gansu, increased female risk of alveolar echinococcosis may be associated with their role as principal care-giver for pets in dog-owning households. Dogs appear to be highly susceptible to infection with E. multilocularis if they eat infected small mammals, while cats appear to have lower susceptibility to infection with the adult tapeworm [15 . . ].
The key to maintenance of the natural parasitic cycle of E. multilocularis is the ecology of the predator-prey relationship between fox species (primarily the red fox, Vulpes vulpes, in Europe and Eurasia) and susceptible small mammal species, especially those that are prone to pluriannual cycles of increased population density: e.g. vole species in the genera Microtus, Arvicola and Clethrionomys. Red fox prevalence rates are usually much higher (20-60%) compared to rates in microtine voles (51-5%). However, transmission is ensured because of seasonal (and/or multi-annual) increase in the abundance of intermediate rodent host populations, with an associated increased tendency for behavioural change in foxes from generalist to specialist predators [28 . . ]. The abundant red fox population in Europe provides an accessible population of definitive hosts for prevalence studies and for mapping geographical distribution of the parasite [29] . Fox necropsy studies, however, are time consuming and biohazardous, so the advent of specific coproantigen ELISA and copro-PCR tests for vulpine echinococcosis has significantly improved the potential for epidemiological and transmission studies of E. multilocularis [30 . . ,31] . Fox surveys in Germany and France in the mid-1990s compared necropsy prevalence rates with data collected from the 1970s and 1980s, and these studies indicated real trends in both increased fox densities and increased prevalence rates [32 . . ,33]. Furthermore, new reports of E. multilocularis in animals have occurred since the 1990s for several European countries previously considered non-endemic: i.e. Belgium, Netherlands, Luxembourg, Czech Republic, Slovak Republic, Poland, Liechtenstein, Italy, Denmark, Slovenia, Bulgaria and Romania [15 . . , 33, 34] . Urban fox populations in the cities of Zurich and Stuttgart have also been identified to be infected with E. multilocularis, with prevalence rates of 20-47% [32 . . ,35 . . ]. Autochthonous human alveolar echinococcosis cases have now been confirmed in some countries outside the historical endemic core region of Europe (i.e. France, Germany, Italy and Austria), and now includes Belgium, Greece and Poland [27] . Concern is therefore growing about potential for increased exposure to the parasite in western and central Europe. Despite the first confirmed alveolar echinococcosis patient in the UK, which was a probable imported case from Afghanistan [37] , no fox infections with E. multilocularis were found in a recent study of *600 animals culled across the UK [36] .
Outside the expanding (?) European focus, human alveolar echinococcosis is of great public health concern in several other regions including the Japanese island of [20 . . ,38 . ]. In China in particular, the application of satellite remote sensing and geographical information systems (GIS) have proved extraordinarily useful in the development of predictive models for risk analysis of human alveolar echinococcosis at the village level [39 . ]. Spatial data analysed from China and France in relation to the distribution of potentially suitable small mammal habitats in partially or substantially cleared (deforested) landscapes, was able to predict villages at high or low risk for human alveolar echinococcosis [20 . . ,27,39 . ]; and in Germany a GIS involving fox data confirmed that open environments with humid soil were most favourable to transmission in an endemic region [40 . ].
Analysis of nucleotide sequence data for a few genes (including that for reduced nicotinamide adenine dinucleotide), in contrast to E. granulosus, did not indicate major genetic heterogeneity in different isolates of E. multilocularis [41] . However, detection of some variation in the 18S rRNA coding region suggests possible geographic differences between Eurasian and Alaskan isolates [42 . ]. Phylogenetic and molecular epidemiological studies will be further enhanced by the recent publication of the complete mitochondrial DNA sequence for E. multilocularis [43 . . ].
Conclusions
Human alveolar echinococcosis (alveolar echinococcosis) is a rare but potentially fatal helminthic zoonosis, for which both diagnosis and treatment are difficult. Increased knowledge of host immune responses and development of better diagnostic tests, together with reliable in-vitro culture systems have improved both detection and treatment potential. Veterinary epidemiological studies indicate increased prevalence and geographic distribution of the parasite in foxes in Europe, while retrospective analysis of hospital data confirms that alveolar echinococcosis is an important zoonosis in western Europe, with significantly more human cases than for bovine spongiform encephalopathy and rabies combined.
Control of the transmission of E. multilocularis will be very difficult, or impractical because of the sylvatic animal hosts involved. Nevertheless, use of praziquantel baits in circumscribed foci of E. multilocularis in Germany was able to significantly reduce prevalence rates in foxes sampled in core control zones as well as peripheral control areas [44 . ]. Development of a vaccine against the metacestode stage in experimental rodents shows promise, but is not a practical approach for transmission control, rather it indicates potential for consideration as a human vaccine. The application of geographical analysis using GIS and remote sensing for management and measurement of medical/veterinary epidemiological related spatial variables have enabled development of prototype predictive models for risk of human alveolar echinococcosis at local and regional scales.
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